Australia’s Pharmaceutical Benefits Scheme (PBS) is set to cover a new cancer medicine for brain cancer, according to reporting that links the timing to the death of prominent cancer researcher Richard Scolyer. Multiple outlets say the decision follows a “massive call” for the drug and that the medicine is priced at about $28,000. The reports note that the approval occurs less than two months after Scolyer’s death. While both sources describe the same core details—PBS coverage, the drug’s relevance to brain cancer, the approximate cost, and the close timeframe after Scolyer’s passing—they do not provide additional granular information in the supplied excerpts, such as the drug’s specific name, eligibility criteria, or the broader clinical justification. The coverage therefore centers on the government’s decision and the timing relative to Scolyer, rather than on detailed treatment outcomes or implementation steps. The reports agree on the key facts presented, but offer limited further context in the provided text.